_PRIVATE_LIMITED.webp)
Synbiopro Nutraceutix (Opc) Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 K
- Company Age 4 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -244.41%
- Ebitda -244.41%
- Net Worth -43.66%
- Total Assets 124.10%
About Synbiopro Nutraceutix (Opc)
Synbiopro Nutraceutix (Opc) Private Limited (SNOPL) is a registered startup operating as a Company incorporated in India on 27 January 2021 (Four years 7 days old ). Its registered office is in Mysore, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 K , as per Ministry of Corporate Affairs (MCA) records.
Aditya Desiraju serves as a director at the Company.
Company Details
-
Location
Mysore, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U15490KA2021OPC143546
-
Company No.
143546
-
Incorporation Date
27 Jan 2021
-
Date of AGM
-
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Synbiopro Nutraceutix (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Desiraju
|
Director | 27-Jan-2021 | Current |
Financial Performance of Synbiopro Nutraceutix (Opc).
Synbiopro Nutraceutix (Opc) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 244.41% decrease in profit. The company's net worth observed a substantial decline by a decrease of 43.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synbiopro Nutraceutix (Opc)?
Unlock access to Synbiopro Nutraceutix (Opc)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Triphase Pharmaceuticals Private LimitedAditya Desiraju is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Synbiopro Nutraceutix (Opc)?
Synbiopro Nutraceutix (Opc) has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synbiopro Nutraceutix (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synbiopro Nutraceutix (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.